Effectiveness Of Ursodeoxycholic Acid In The Management Of Symptomatic Gallstone Disease: A Cross Sectional Study
DOI:
https://doi.org/10.63682/jns.v14i32S.9986Keywords:
Ursodeoxycholic acid, gallstone disease, cholelithiasis, conservative management, biliary colicAbstract
Background: Gallstone disease is a frequently encountered hepatobiliary condition that commonly presents with biliary colic and dyspeptic complaints. Ursodeoxycholic acid (UDCA) has emerged as a conservative therapeutic option for selected patients with cholesterol gallstones; however, evidence regarding its effectiveness in symptomatic cases from routine clinical practice remains limited.
Objective: To assess the effectiveness of Ursodeoxycholic acid in alleviating symptoms and reducing gallstone burden in patients with symptomatic gallstone disease.
Methods: This cross-sectional study included patients diagnosed with symptomatic gallstone disease who were treated with Ursodeoxycholic acid. Clinical symptoms, ultrasonographic findings, and treatment outcomes were evaluated and analyzed statistically.
Results: A significant reduction in pain and dyspeptic symptoms was observed following therapy. Ultrasonographic follow-up revealed partial or complete dissolution of gallstones in a proportion of patients, particularly those with smaller cholesterol stones.
Conclusion: Ursodeoxycholic acid represents an effective and non-invasive treatment modality for symptom control and gallstone reduction in carefully selected patients with symptomatic gallstone disease.
Downloads
References
[1] Shaffer EA. Epidemiology of gallstone disease. Best Pract Res Clin Gastroenterol. 2006.
[2] Wang HH, Portincasa P. Pathogenesis of cholesterol gallstones. Hepatology. 2007.
[3] Ko CW, Sekijima JH. Gallstone disease: Symptoms and diagnosis. Lancet. 2006.
[4] Strasberg SM. Laparoscopic cholecystectomy standards. Ann Surg. 2002.
[5] Tazuma S. Medical therapy for gallstone disease. Best Pract Res Clin Gastroenterol. 2006.
[6] Paumgartner G, Beuers U. Mechanisms of action of UDCA. Clin Liver Dis. 2004.
[7] Stolk MF, et al. Gallstone dissolution therapy. Aliment Pharmacol Ther. 2000.
[8] van Erpecum KJ. Gallstone disease management. BMJ. 2010.
[9] Di Ciaula A, Wang DQH. Non-surgical treatment of gallstones. World J Gastroenterol. 2012.
[10] EASL Clinical Practice Guidelines. Gallstones. J Hepatol. 2016.
[11] Sandler RS, et al. Burden of digestive diseases. Gastroenterology. 2002.
[12] Tomida S, et al. UDCA in symptomatic gallstones. Hepatogastroenterology. 2003.
[13] Beuers U. Bile acid therapy mechanisms. Gut. 2006.
[14] Shiffman ML. Gallstone dissolution predictors. Am J Gastroenterol. 2002.
[15] Wang DQH. Biliary lipid secretion and gallstones. Gastroenterology. 2009.
[16] Lazaridis KN, et al. Cytoprotective effects of UDCA. Hepatology. 2001.
[17] Sugiyama M. Conservative management of gallstones. Curr Opin Gastroenterol. 2005.
[18] Mendez-Sanchez N. Recurrence after dissolution therapy. Gut. 2008.
[19] European Association for the Study of the Liver. Gallstone guidelines. J Hepatol. 2016.
Stinton LM, Shaffer EA. Future directions in gallstone therapy. Nat Rev Gastroenterol Hepatol. 2012.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
